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Abstract 
A variety of injuries, such as bacterial infection or ischemic tissue necrosis, induce systemic acute phase reaction expressed as fever, 
leukocytosis, release of several hormones, activation of clotting, complement and kinin forming pathways, and drastic increase of 
synthesis of certain plasma proteins. The reaction is triggered by 'alarm molecules', including free radicals, which activate several 
stress-sensitive protein kinases (ERK, p38, JNK) in macrophages and other responsive cells. These kinases phosphorylate, usually in a 
multi-step cascade, transcription factors belonging primarily to C/EBP, NF-KB and AP-1 families. Active transcription factors after 
translocation to nucleus interact with responsive lements in the gene promoters of acute-phase cytokines: tumor necrosis factor-a, 
interleukin-1 and interleukin-6. Enhanced transcription of these genes is usually followed by rapid translation and precursor protein 
processing leading to the release of biologically active cytokines. Fine tuning of the acute phase response appears to be regulated at all 
stages: primary signals, kinase cascades, transcription factors, mRNA stability and translation, cytokine precursor processing, secretion 
and bioavailability. This makes possible designing of specific inhibitors of cytokine synthesis as potential therapeutic drugs. 
1. Acute phase response 
The acute phase response represents an early and unspe- 
cific but highly complex reaction of the animal organism 
to a variety of injuries such as bacterial, viral or parasitic 
infection, mechanical or thermal trauma, ischaemic necro- 
sis or malignant growth (for Refs. see [1-3]). The se- 
quence of events following injury can be depicted as a 
cascade (Fig. 1). The local reaction, if occurs, is mani- 
fested as acute inflammation whereas systemic reaction 
includes neurological, endocrine and metabolic alterations 
which are expressed as fever, leukocytosis, increased re- 
lease of several hormones, activation of the clotting, com- 
plement and kinin-forming pathways, and drastic rear- 
rangement of plasma protein synthesis (acute phase pro- 
teins). It has been generally accepted that acute phase 
response is beneficial helping to restore homeostasis dis- 
turbed by the injury, but excessive production of inflam- 
matory mediators may have negative or even lethal effects 
(e.g. in septic shock). Extensive research in the field of 
acute phase response, especially in respect to induced 
synthesis of acute phase proteins in liver cells, have been 
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reviewed in numerous papers, conference reports and 
books. However, the molecular mechanism of initiation of 
the acute phase response is still poorly understood and this 
review is aimed at closing the gap and presenting recent 
advances in the field. For the sake of brevity only some 
original contributions could be quoted, the reader being 
referred to other review papers. 
2. Inflammatory mediators and cytokine network 
Tissue macrophage is a cell most commonly regarded 
as initiating the acute phase response, although the role of 
polymorphonuclear leukocytes, platelets, T-lymphocytes, 
endothelial cells and fibroblasts hould not be overlooked. 
Activated macrophages release a broad spectrum of media- 
tors [4,5] free radicals and reactive oxygen species (per- 
oxide, nitric oxide), derivatives of lipids (prostaglandin E2, 
tromboxane A2, platelet activating factor), and a variety of 
regulatory proteins (cytokines). 
A considerable degree of confusion in respect o nature 
and nomenclature of cytokines arises from the fact that this 
class of mediators includes interleukins and hematopoietic 
regulators, interferons, various cellular growth and differ- 
entiation factors, and some chemotactic polypeptides [6- 
13] (Table 1). As defined by Nathan and Sporn [6] 'cyto- 
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Fig. 1. Simplified cascade of the acute phase response. For further 
explanations see text (Section 1, 2). 
kine is a soluble (glyco)protein, on-immunoglobulin in 
nature, released by living cells of the host, which acts 
non-enzymically in picomolar to nanomolar concentrations 
to regulate host cell function. Cytokines make up the 
fourth major class of soluble intercellular signaling 
molecules, alongside neurotransmitters, endocrine hor- 
mones and autacoids'. Majority of cytokines are multifunc- 
tional and exhibit pleiotropic effects eliciting response in 
Table 1 
Major groups of cytokines (modified from [7]) 
Interleukins and Colony-stimulating- Cellular growth 
related factors factors factors 
IL- 1 ce GM-CSF EGF 
IL- 1/3 G-CSF TGF-a 
TNFo~ M-CSF aFGF 
TNFfl EPO bFGF 
IL-2 Steel factor KGF 
IL-3 PDGF-A 
IL-4 Chemotaetic factors PDGF-B 
IL-5 IL-8 (NAP- 1) NGF-/3 
IL-6, LIF MCP- 1 IGF-I 
OSM, CNTF, CT-1 GRO IGF-II 
IL-7 RANTES HGF-SF 
IL-9 
IL- 10 TGF-/~ family Interferons 
IL- 11 TGF-fl 1 IFNa 
IL- 12 TGF-/3 2 IFN/3 
IL- 13 inhibin IFN7 
IL- 14 actibin 
IL-15 
The list is not complete, for further references and abbreviations see 
[6-9,12]. 
widely different cell types [14,15]. At the same time many 
cytokines how a considerable degree of redundancy which 
is possible due to sharing receptor subunits or other ele- 
ments of signaling pathway [3,15-19]. The most conspicu- 
ous functional overlapping occurs probably among IL-6- 
type cytokines which share gpl30 receptor subunit respon- 
sible for signal transduction [12]. However, IL-6 plays a 
major role in this group as indicated by impaired immune 
and acute-phase r sponses in knockout mice with experi- 
mentally disrupted IL-6 gene [20]. In vivo cytokines oper- 
ate as intricate network involving different cytokine pro- 
ducing and responding cells, specific receptors and their 
antagonists [10], and additional modulators and inhibitors, 
including hormones uch as glucocorticoids and insulin 
[2,3,14,21]. 
Arbitrarily, acute phase cytokines can be divided into 
three groups (for Ref., see [22]): 
- -  Proinflammatory c tokines initiating or enhancing 
the cascade of events: TNFa, IL-1, IFNT and IL-8. 
- -  Interleukin-6-type cytokines including IL-6, 
leukemia inhibitory factor (LIF), interleukin-ll (IL-11), 
oncostatin M (OSM), ciliary neurotrophic factor (CNTF) 
and cardiotrophin-1 (CT-1) which are held responsible for 
the main systemic features of acute phase response in a 
variety of tissues, ranging from bone marrow to liver. 
- -  Antiinflammatory cytokines down-regulating the 
acute phase response: interleukin-10 (IL-10), interleukin-4 
(IL-4), interleukin-13 (IL-13) and transforming rowth 
factor-/3 (see also [23]). 
This classification is certainly oversimplified since some 
cytokines play various roles depending on the stage of 
inflammation (IL-6), while others behave as modulators 
(e.g. TGF-/3, hepatocyte growth factor [21,24]). The sub- 
ject of induced cytokine synthesis is very broad and this 
review will be mainly concerned with IL-1, TNF, IL-8 and 
IL-6-type cytokines. The sequence of events during in- 
duced synthesis of acute phase cytokines is still disputable 
but it has been established that TNF and IL-1 are produced 
earlier than IL-6 [25-27] and may directly stimulate IL-6 
synthesis [28,29]. 
3. A la rm molecu les  induc ing  synthes is  o f  acute  phase  
cytok ines  
Acute phase response is a primary defense reaction and 
therefore bacterial products uch as endotoxin (LPS) are 
probably the most potent inducers of TNF, IL-1 and IL-6 
[30,31,26,27,10,32]. Interaction of endotoxin with target 
cells is facilitated by a specific LPS-binding protein (LBP) 
[33]. LBP binds with a high affinity to the lipid portion of 
LPS and then interacts with the monocyte differentiation 
antigen CD-14 to upregulate synthesis of acute phase 
cytokines [34]. Production of IL-6 and other cytokines in 
cultured mononuclear cells can be induced or enhanced by 
IL-1 or TNF in the autocrine loop but is independently 
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stimulated by some viruses and synthetic polynucleotides, 
by a variety of second messengers (cyclic AMP, prosta- 
glandins, diacylglycerol) and their agonists (phorbol esters, 
forskolin) and even by serum [35]. 
However, the primary signals eliciting synthesis of acute 
phase cytokines in aseptic tissue necrosis, such as myocar- 
dial infarction, remain poorly understood, although it has 
been found that hypoxic stress directly induces IL-6 in 
cultured cardiac myocytes [36] and in vascular cells [37]. 
Among candidates to function as 'alarm molecules' are 
free radicals, prostaglandins and even modified proteins 
acting as foreign materials. The in vivo reaction is cer- 
tainly complex and involves activation of the complement 
system, accumulation of leukocytes, timulation of cyclo- 
oxygenase-lipooxygenase p thways, generation of free rad- 
icals and induction of intercellular adhesion molecules 
[38,39]. 
Free radicals may affect cytokine-producing cells di- 
rectly or through the modification of proteins in the extra- 
cellular fluids. Proteins altered by these radicals, or by 
leukocyte and tissue proteinases, will be taken up by 
macrophages, fibroblasts or endothelial cells, and by un- 
known mechanisms switch on the synthesis of acute phase 
cytokines. Indeed, fibrinogen degradation products, serpins 
modified by proteinases and derivatives of complement 
component C5a were found to increase production of TNF, 
IL-1 and IL-6 in cultured human and rat macrophages (for 
Refs., see [22,40-43]). Since cell adherence to some solid 
surfaces [44] and phagocytosis of foreign materials free of 
endotoxin [45,22] may stimulate synthesis of TNF, IL-1 
and IL-6, it is clear that multiple cellular signaling path- 
ways are being used for inducing cytokine synthesis. 
by a rapid fall that results in part from the synthesis of a 
transcriptional repressor as well as a decrease in mRNA 
half-life. Certain stimulants, uch as complement compo- 
nents, cell adherence or blood clotting induce accumula- 
tion of large amounts of IL-1/3 mRNA in monocytic ells 
without significant ranslation into the cytokine protein, 
while endotoxin induces both transcription and translation 
[10,11,551. 
The structure of the IL-6 gene has been dissected in 
detail: positive and negative transcription regulatory ele- 
ments of the human IL-6 gene are located predominantly 
in the region proximal to the start site [49,12,50]. As 
shown in Fig. 2 the multiple response lements in the IL-6 
promoter epresent he common and overlapping DNA 
targets for a variety of different activation pathways. Ex- 
pression of IL-6 gene in mononuclear cells can be induced 
by numerous factors listed in Section 3. 
Synthesis of acute phase cytokines is inhibited by glu- 
cocorticoids and some other steroid hormones with the 
involvement of complex mechanisms [55,56,11]. The inhi- 
bition may result from occlusion of positive responsive 
sequences by binding of glucocorticoid receptor to specific 
DNA domain [48], by direct interaction of glucocorticoid 
receptor with subunits of the transcription factor NF-KB 
[57], or by decreasing IL-6 mRNA stability [58]. It is 
supposed that AU rich sequences in the 3' untranslated 
region of the mRNA of many cytokines and oncogenes are 
responsible for this instability [59-61]. However, Stein and 
Yang [50] reported that estrogen receptor may repress IL-6 
promoter by direct interaction with some transcription 
factors and Ohtsuka et al. [62] demonstrated that glucocor- 
ticoid-mediated inhibition of IL-8 induction by LPS or 
IL-1 occurs at the stage of NF-KB activation. 
4. Cytokine genes and their expression 
Majority of cytokine genes have been cloned and se- 
quenced providing detailed information about their pro- 
moter egions, with IL-1, IL-6 and TNF as the best known 
examples (for Refs., see [10-12,46-53]). A striking fea- 
ture of these promoters i abundance of multiple regulatory 
elements, often occurring in repetitions and different com- 
binations with various degree of homology and consensus 
sequences. 
In case of IL-1/3 gene sequences responding to serum, 
phorbol esters (PMA), cAMP, endotoxin and other cy- 
tokines were found in the region proximal to the transcrip- 
tion start site ( -512 to -133 bp) and in the distal region 
( -2800 to -1720 bp) [54,46,11]. Both proximal and 
distal promoter elements appear necessary for the tissue- 
specific and inducible expression. It is interesting that the 
promoter for IL-1 ct does not contain a TATA box in 
distinction to IL-1/3 promoter [54]. When human mononu- 
clear cells are stimulated with bacterial endotoxin, mRNA 
for either IL- la  or IL-1/3 is detected in the cell within 15 
min [10]. IL-!/3 mRNA accumulates for 4 hours followed 
5. Major transcription factors involved in cytokine gene 
expression 
Currently available data indicate that several major 
families of transcription factors participate in the basal and 
induced expression of acute phase cytokines, the most 
important being C/EBP, AP-1 and NF-KB. 
CAAT/enhancer binding protein (C/EBP protein), 
cloned first in 1988, binds to two distinct sites: the CAAT 
box of several mammalian promoters, and to the core 
homology TGT(A/T)(A/T)(A/T)G of several viral en- 
hancers (for Ref. see [63]). Seven members of C/EBP 
family identified so far share three structural components: 
C-terminal leucine zipper, a basic DNA-binding region and 
a N-terminal transactivating region. An optimal palin- 
dromic C/EBP binding site, GATrGCGCAATC has been 
artificially designed and natural binding sites may differ 
and show homology to only one half of the palindrome. 
Several of C/EBP genes have been repeatedly cloned by 
different investigators and thus many synonyms exist. 
C/EBPfl involved in the expression of both acute phase 
A. Koj / Biochimica et Biophysica Acta 1317 (1996) 84-94 87 
cytokine genes and cytok ine- induc ib le  acute-phase pro- 
teins is known also as NF- IL6  (man),  I L -6DBP (rat) or 
AGP/EBP  (mouse)  (for the full l ist see [63]). 
Mult ip le  target genes in var iety of  t issues have been 
reported for C /EBP  family.  In l iver parenchymal  cells 
C /EBP  proteins have been shown to form const i tut ive and 
inducible complexes  on IL-1- and IL -6-responsive ele- 
ments  of  acute phase protein genes. Whi le  C /EBPa  and/3  
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Fig. 2. Principal regulatory elements of the human IL-6 promoter (A: from Ray et al. [48]; B: from Dendorfer et al. 175], with permission). A. Solid lines 
(either boxes or arrows) indicate DNA regulatory elements that have already been functionally implicated in IL-6 gene expression, while those marked by 
broken lines or boxes are based on DNA sequence analyses. The inducible transcription start sites were derived by S1 nuclease mapping (ratio of major 
+ 1 to minor - 21 was 99:1). The presence of a negative regulatory domain (NRD) between - 225 and - 165 was inferred from results published earlier. 
The typical GACGTCA CRE/TRE motif in MRE I and the nucleotides in the novel CRE/TRE in MRE II which match with nucleotides in the CRE 
identified in bovine CYP17 are highlightened by solid circles. The mutation of the CG residues to GT reduces the responsiveness of MRE I to TPA and 
forskolin. PRD II refers to the NF-KB-like domain in the beta interferon promoter; Inr refers to the initiator RNA start site motif as functionally 
characterized in the terminal deoxynucleotidyltransferase (TdT) gene. RCE is the Rb-repressible DNA target in the c-fos promoter• B. Putative 
cis-regulatory elements of the human IL-6 promoter with their appropriate locations relative to the major transcription site (+ 1). Abbreviations: GRE, 
glucocorticoid response lement; SRE, serum response lement. Below, sequences of the individuasl transcription factor binding sites are indicated together 
with the mutations used (altered nucleotides underlined). 
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may be responsible for constitutive transcription of these 
genes, the /3 and ~ isoforms appear to predominate in the 
IL-6-induced expression of such proteins as human C3 
complement component [64] or mouse serum amyloid A3 
[65]. C/EBP6 is activated by phosphorylation [66,28], 
similarly as structurally unrelated acute phase response 
factor (APRF) involved in the regulation of class 2 acute 
phase proteins [67]. 
C/EBP/3 and especially C/EBP6 are highly inducible 
or activated via several signaling pathways in multiple 
tissues including monocytes/macrophages during the acute 
phase response elicited by LPS [68,69]. These C/EBP 
isoforms participate in the induced expression of IL-1/3 
[70], TNFa [71], IL-6 and IL-8 [72], and other cytokines 
(for further Ref. see [63]). Apart from constitutive and 
LPS-induced synthesis of cytokines C/EBP/3 plays a cen- 
tral role in the induction of IL-6 by hypoxia in vascular 
cells [37]. As demonstrated by Margulies and Sehgal [73] 
participation of C/EBP/3 in IL-6 induction can be blocked 
by a wild type tumor suppressor protein p53 but not by its 
mutants. The role of C/EBP family in expression of 
human IL-6 is extensively discussed by Sehgal et al. [12]. 
The leucine zipper is also a prominent feature of the 
activator protein (AP-1) transcription factor identified 
firstly in human metallothionein gene (for Ref. see [74]). 
AP-1 consists of either Jun homodimers or Fos/Jun het- 
erodimeric omplexes which bind to palindromic sequence 
TRE (phorbol ester TPA-responsive element) 
TGA(C/G)TCA. TRE sequences are present in numerous 
mammalian promoters, including acute phase proteins, cy- 
tokines and cellular growth factors [74]. 
Two almost identical AP-1 sequences have been identi- 
fied in the human and mouse promoter of IL-6 gene (Fig. 2 
and [12,75,76]). According to Kick et al. [76] the UV light 
or photodynamic therapy induce expression of IL-6 by 
selective activation of the distal AP-1 binding site but 
involvement of both AP-1 and NF-KB in response to UV 
light is well documented [77]. Although AP-1 and NF-KB 
have different structure and bind to distinct enhancer mo- 
tifs it has been shown that c-Fos and c-Jun are capable of 
physically reacting with NF-KB p65 subunit and the result- 
ing heterodimer shows functional synergy [78]. 
The name of nuclear factor NF-KB was coined after its 
discovery in B-cells expressing immunoglobulin kappa 
chain, but later its ubiquitous presence in mammalian cells 
have been found [79]. The DNA binding nuclear form of 
NF-KB is usually a heterodimer with typically one 50 kDa 
(p50) and one 65 kDa (p65) polypeptide (for Ref. see 
[80]). The two subunits how characteristic Rel-homology 
region, occur in five isoforms [81] and bind to specific 
DNA regions. A detailed structure of such protein-DNA 
complex has been recently described [82]. The highest 
DNA affinity is exhibited by heterodimer recognizing fre- 
quent motif GGGACTTTCC with numerous variations. In 
cytosol NF-KB dimers occur in complex with one of the 
isoforms (c~,fl or y) of the inhibitory protein IKB. IKBc~ 
is presumably identical to a protein MAD3 (37-43 kDa) 
recently cloned from monocytes and easily undergoing 
phosphorylation at serine or threonine residues [83]. After 
phosphorylation I KB dissociates from the p65-p50 com- 
plex and is then proteolytically degraded [84,80]. 
Regulatory promoter regions with NF-KB binding sites 
are common in genes primarily involved in processes that 
respond to external challenges: inflammation, immune re- 
actions and the acute phase response. Activation of cy- 
tokine gene expression by NF-KB is probably the most 
important pathway but for the maximum response addi- 
tional factors are also required. They act through multiple 
response lements (MRE, Fig. 2) sensitive to serum and 
cyclic AMP (CRE) [75,46]. Cooperation of C/EBP family 
transcription factors with NF-K B in the expression of IL-6 
in differentiating bovine monocytes was studied by Ray 
and Ray [51]. They found interaction of C/EBPa, 
C/EBP//3, NF-KB1 (p50) and NF-KBRel (p65) to be 
required for full induction of IL-6 gene by LPS. Since the 
Ets domain (related to v-ets oncogene) is also present in 
IL-6 promoter (Fig. 2) participation of transcription factors 
from Ets family in the expression of cytokine genes hould 
be considered, especially in cooperation with AP-I [85]. 
Sanceau et al. [86] demonstrated that contribution of 
IFN-y to the triggering of IL-6 gene in human monocytic 
THP-1 cells involves a change in the amount of phospho- 
rylated transcription factor SP-1, together with the induc- 
tion and activation of interferon regulatory factor (IRF-1). 
These factors cooperate synergistically with homodimer 
p65-NF-KB, which is activated by TNF. As reported by 
Dewitt et al. [87] IFN-y downregulates AP-1 but enhances 
p65 expression i  LPS-stimulated human monocytes. 
6. Intracellular signaling pathways for induction of 
cytokines and the effect of redox potential of the cell 
It is interesting that similar elements of signal transduc- 
tion machinery are being used for eliciting biological 
effects of cytokines and induction of their synthesis. Some 
cellular growth factors bind to receptors exhibiting intrin- 
sic protein tyrosine kinase activity and directly generate a 
complex signaling cascade which involves Ras and Raf-1 
oncogenes and mitogen activated protein kinases (MAPKs) 
[88,89]. On the other hand, several cytokines, including the 
acute phase family, interact with receptors lacking catalytic 
domain. In this case, binding of the ligand leads to cluster- 
ing of receptors and interaction of their cytoplasmic do- 
mains with a special class of protein tyrosine kinases 
called collectively Janus kinases (JAKs). As reviewed by 
Ihle et al. [90], Lamer and Finbloom [17], Schindler and 
Darnell [19] and Kishimoto et al. [91] JAKs physically 
associate with the membrane-proximal region of a ligand- 
bound receptor, and this leads to their tyrosine phosphory- 
lation and activation. It is likely that activated JAKs 
phosphorylate the receptors as well as cytoplasmic proteins 
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Fig. 3. Signal transduction pathways for NF-KB activation (from Suzuki et al. [72], with permission, 1994, American Association of Immunologists). 
Activation of NF-KB can be achieved by a variety of stimuli, including cytokines uch as TNF-ot and lymphotoxin, which bind to their receptors, and 
PMA, which activates protein kinase C. These stimuli produce second messengers, likely reactive oxygen species; this step can be blocked by antioxidants. 
Oxidation of a serine/threonine protein kinase, which is redox sensitive to stimulation by reactive oxygen species, may result in phosphorylation f an as 
yet unidentified mediator. Okadaic acid and calyculin A, which inhibit the activity of PP-1 and PP-2A, also, in turn, allow the accumulation of the 
phosphorylated product. Phosphorylation results in dissociation of the I K B subunit from NF-K B molecule, and NF-K B becomes activated. The dissociated 
I K B is degraded by a chyrnotrypsin-like protease, the activity of which can be inhibited by TPCK. Activated NF-K B migrates to the nucleus and binds to 
the consensus DNA sequence, resulting in gene activation. 
Table 2 
Schematic illustration of the two levels of redox control and the mediators involved (from [100], with permission) 
Transcription factor I st level: redox modulation of induction/activation 2nd level: redox modulation of DNA-binding activity 
NFK B positive mediators: negative mediator: 
H202/GSSG (oxidative induction GSSG (oxidative inhibition by mixed 
of NFK B activation and disulphide formation at a 
nuclear translocation) redox-reactive cysteine in 
the DNA binding region) 
positive mediator: 
reduced thioredoxin 
AP-I 
negative mediator: 
reduced thioredoxin 
positive mediators: 
ROI/GSSG? (oxidative activation 
of AP-1 via Jun phosphorylation) 
reduced thioredoxin 
(activation of c-fos gene 
transcription) 
negative mediator: 
oxidized thioredoxin (oxidation 
of a redox reactive cysteine 
in the DNA binding region?) 
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belonging to a family of transcription factors called the 
'signal transducers and activators of transcription' 
(STATs). This signaling pathway is shared by several 
members of the cytokine receptor superfamily including 
receptors for IFN-a or IL6-type cytokines. It should be 
mentioned here that the acute phase response factor (APRF) 
held responsible for transcription of class 2 acute phase 
proteins [67] has been recently identified as STAT3 protein 
[90]. On the other hand, signal transduction from activated 
IL-1 receptor involves small GTP-binding proteins and 
MAP kinases [11 ]. 
Although the JAK-STAT pathway and action of MAP 
kinases may explain activation of target genes for cy- 
tokines and reciprocal induction of cytokines within their 
complex network, they fail to elucidate the primary events 
of acute phase response. Such events can be best analyzed 
by injury-elicited mechanism of NF-KB and AP-1 activa- 
tion emphasizing the role of reactive oxygen intermediates 
(Fig. 3 and [92]). 
These intermediates and other free radicals are gener- 
ated in monocytes/macrophages and leukocytes by expo- 
sure to endotoxin, bacteria, viruses or foreign materials, 
and in certain tissues by reperfusion injury. As shown by 
Chaudri and Clark [93] hydrogen peroxide or sodium 
periodate stimulate synthesis of TNF in mouse peritoneal 
macrophages, and Schreck et al. [94] reported activation of 
NF-KB by hydrogen peroxide and butyl peroxide in cy- 
tokine-producing lymphoma nd carcinoma cell lines. It 
should be added that in experiments described by Schreck 
et al. [94] other oxygen reactive species, such as singlet 
oxygen or 0 2 were ineffective. 
Redox regulation of the Fos/Jun complex in AP-1 is 
also well documented. Reactive oxygen intermediates are 
implicated in activation of c-jun gene by ionizing radiation 
[92,95], and c-Fos-containing AP-1 heterodimers were 
found to increase during photodynamic therapy associated 
with IL-6 expression [76]. Priming of human promonocytic 
U937 cells for IL-1/3 production by exposure to nontoxic 
concentrations of H202 was accompanied by enhanced 
nuclear AP-1 in activated cells [96]. 
The importance of reactive oxygen intermediates in
NF-KB activation and cytokine induction is emphasized by 
numerous reports demonstrating that both events can be 
inhibited by some antioxidants uch as N-acetyl-L-cy- 
steine, lipoic acid, pyrrolidine dithiocarbamate, tetrahy- 
dropapaveroline (THP) or nordihydroguaiaretic acid 
[97,94,45,98]. As pointed out by Eugui et al. [45] the most 
potent were moderately lipophylic agents, whereas typical 
hydrophilic antioxidants, uch as ascorbic acid, or typical 
lipophylic agents, such as tocopherol r butylated hydrozy- 
toluene, had little effect. Similarly ineffective was manni- 
tol, a hydroxyl radical scavenger, and zileuton, inhibitor of 
5-1ipooxygenase, suggesting that lipooxygenase products 
are not directly involved in the signal transduction leading 
to cytokine synthesis in LPS-stimulated monocytes. Of the 
compounds tested, tetrahydropapaveroline decreased the 
concentration of NF-KB and AP-1 detected by elec- 
trophoretic mobility shift assay in nuclear extracts of hu- 
man peripheral blood monocytes cultured in the presence 
or absence of LPS [45]. Experiments with cycloheximide 
suggest hat these antioxidants prevent he activation of 
NF-KB and AP-1 rather than their formation. However, 
the active compounds did not inhibit IL-l-induced produc- 
tion of IL-6 in dermal and synovial fibroblasts uggesting 
the existence of alternative signaling pathways depending 
on cell type and/or stimulus applied [45]. 
A possible site of action of antioxidants in a postulated 
cascade involving NF-KB is depicted in Fig. 3 [92]. Re- 
dox-sensitive serine-threonine kinases involved in phos- 
phorylation and inactivation of IKB represent the most 
likely target. Despite the initial report [99] probably more 
than one kinase can phosphorylate NF-KB complex or 
I K B which immediately dissociates from Rel heterodimer 
and is quickly degraded by a chymotrypsin-like or multi- 
catalytic proteinase. 
As emphasized by Galter et al. [100] oxidative condi- 
tions potentiate activation of NF-KB and AP-1 in intact 
cells but are able to inhibit affinity of these transcription 
factors for specific DNA sequences, presumably by block- 
ing sulphydryl groups in DNA-binding domains. A deriva- 
tive of ubiquitous tripeptide, glutathione disulphide 
(GSSG), may be responsible for both effects, since the 
ratio of GSH/GSSG varies considerably depending on 
metabolic state of the cell. As shown in Table 2 a certain 
optimal level of GSSG may be required for NF-KB and 
AP-I activation while an excess of GSSG may inhibit 
NF-kB at the level of DNA binding. Both effects may be 
counter regulated by reduced thioredoxin (Table 2 and 
[101,102]). Recently, Schenk et al. [103] reported that 
thioredoxin strongly enhanced induced synthesis of TNFo~, 
IL-1 o~ and IL-8 in various mammalian cells. Although the 
concept of controlling cytokine synthesis by cellular edox 
potential requires further elaboration it certainly permits to 
reconcile some conflicting reports on the mechanism of 
cytokine induction. 
7. Importance of stress-sensitive protein kinases in initi- 
ating cytokine synthesis 
The crucial question remains how the cell detects multi- 
plicity of signals disturbing homeostasis that lead to in- 
duced synthesis of acute phase cytokines. One of the 
possible xplanations i  the involvement of stress-activated 
protein kinases (SAPKs) [104] and mitogen-activated pro- 
tein kinases (MAPKs) [88]. MAPK pathways erve differ- 
ent roles but the kinases are usually activated by dual 
phosphorylation Thr and Tyr. The sites of phosphoryla- 
tion are located in the tripeptide motif Thr-Glu-Tyr, Thr- 
Gly-Tyr or Thr-Asn-Tyr. MAP kinases can be grouped 
into at least two major classes; extracellular-signal-regu- 
lated kinases (ERKs) and c-Jun N-terminal kinases (JNKs), 
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Fig. 4. Mammalian MAP kinases form an integrated network of signal 
transduction pathways (from Raingeaud et al. [105], with permission, 
1995, The American Society for Biochemistry and Molecular Biology). 
The major stimuli that activate JNK and p38 MAP kinases are pro-in- 
flammatory cytokines and environmental stress. In contrast, the ERK 
group of MAP kinases are activated in cells treated with EGF or phorbol 
ester. This difference is accounted for, in part, by the substrate specifici- 
ties of the MAP kinase kinases MEK1, MEK2, MKK3 and MKK4 which 
activate ERK, p38, and JNK. 
the latter being probably identical to SAPKs [105]. The 
ERK group regulates multiple targets in response to growth 
factors via a Ras-dependent mechanism, whereas JNK 
activates c-Jun (component of the transcription factor AP- 1) 
in response to pro-inflammatory cytokines and exposure of 
cells to various forms of environmental stress (see Fig. 4). 
Recently, a novel mammalian MAP kinase (p38) was 
identified by Han et al. [ 106] and shown to take part in the 
expression of proinflammatory c tokines [107,108]. It is 
activated by such different factors as hyperosmolar 
medium, heat shock, UV radiation, inhibitors of protein 
synthesis and TNF or IL-1 (for further Refs. see 
[88,104,105,109]). As demonstrated by Shapiro and 
Dinarello [110] osmotic shock and IL-1 utilize the same 
mitogen-activated protein kinase for signal transduction 
(Cytosol) 
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m RNA5 '- m G . AUUUA__A,AAAA3 '  
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Cytokine proteins ITNF. IL-1, IL-6] 
Fig. 5. Model of stress-induced cytokine synthesis. For further explana- 
tions see Section 7. 
and stimulation of IL-8 synthesis n human blood mononu- 
clear cells at the level of transcription. Also the signal 
elicited by UV light appears directly in the cytosol since it 
can be elicited in enucleated cells and involves phosphory- 
lation of AP-1 and NF-KB [77]. 
All these MAP kinases can activate transcription factors 
but evidence has accumulated that cytokine synthesis is 
also regulated at the posttranscriptional level with the 
involvement of protein kinases. Recently Lee and co- 
workers [107] studying the mechanism of action of cy- 
tokine suppressive antiinflammatory drug (CSAID) be- 
longing to bicyclic imidazoles (SK&F 86002) described a
pair of mitogen-activated protein kinases, termed CSBPs. 
Binding of piridynyl-imidazole compounds inhibited CSBP 
kinase activity required for dissociation of 37-40 kDa 
regulatory protein which blocks translation of cytokine 
mRNA. The protein is associated with AUUUA sequence 
implicated in mRNA stability [61] but it also interacts with 
the 5'end of mRNA thus preventing translational initiation. 
As suggested by Lee et al. [107,108] this block could be 
relieved by phosphorylation through the CSBP kinase 
pathway which then causes release of the AUUUA-binding 
protein and translational derepression of TNFa and IL- 1/3. 
The piridynyl-imidazole cytokine synthesis inhibitor, by 
interfering with CSBP pathway, would prevent this transla- 
tional derepression. 
Another block in cytokine mRNA translation was re- 
cently described by Kaspar and Gehrke [55] who found 
that enhanced transcription of IL-1/3 gene in human pe- 
ripheral blood monocytes timulated with C5a is not ac- 
companied by IL- 1/3 protein accumulation i  distinction to 
LPS-induced gene. Apparently independent transcriptional 
and translational signals are required for IL- 1/3 expression. 
Perhaps C5a stimulation does not activate CSBP kinase, 
but this must be elucidated by further studies. In distinc- 
tion to IL-1/3, IL-8 appears to be regulated mainly at the 
transcriptional level [ 111 ]. 
The model presented in Fig. 5 emphasizes the role of 
stress-sensitive protein kinases that may regulate cytokine 
synthesis at the level of either transcription or translation 
and thus initiate the acute phase 
8. Posttranslationai cytokine precursor processing, se- 
cretion and transport in body fluids 
Translation of cytokine mRNAs leads to the appearance 
of precursor forms which are usually processed by specific 
proteinases before secretion. Because of the lack of a 
leader peptide, IL- 1 a remains cytosolic but after myristoy- 
lation is inserted in the cell-surface membrane. Any pre- 
cursor interleukin-1 oz(proIL-1 ol) escaping from the cell is 
cleaved to a mature form by extracellular unspecified 
proteinases [10]. On the other hand, prolL-1/3 (31 kDa) 
requires cleavage to a much smaller protein (17 kDa) for 
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optimal secretion and biological activity. The IL-1/3 con- 
verting enzyme (ICE) is an intracellular cysteine pro- 
teinase cleaving prolL-1/3 at the aspartic acid-alanine 
residue [112] and it occurs in several isoforms [11]. Inhibi- 
tion of ICE by some peptide [113] or quinone derivatives 
[114] may reduce biological effects of IL-1 induction and 
secretion. 
There are two forms of TNFa: a type II membrane 
protein (26 kDa) and a soluble (17 kDa) form generated 
from the cell-bound protein by proteolytic leavage [115]. 
A broad spectrum synthetic inhibitors of matrix metallo- 
proteinases prevent he processing of the TNF precursor 
but do not inhibit the release of other cytokines [116]. 
These inhibitors represent potential drugs reducing inflam- 
matory or even lethal effects of TNF [115]. 
IL-8 is generated as a precursor of 99 amino acids, and 
is secreted after cleavage of a typical signal peptide of 20 
residues [117]. The mature protein is processed at the 
N-terminus by neutrophil proteinases yielding several bio- 
logically active forms which are more resistant to further 
degradation and at the same time more potent in chemo- 
taxis [117]. 
Natural human IL-6 consists of a set of differentially 
modified phosphoglycoproteins of molecular mass in the 
range of 23 to 30 kDa [118]. However, in the circulation 
IL-6 occurs predominantly as high molecular mass com- 
plexes with other proteins, including antibodies [119] and 
soluble IL-6 receptors [120]. Complexed or 'chaperoned' 
circulating IL-6 exhibits differential immunoreactivity and 
bioavailability [ 12,121 ]. 
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4, 
INDUCED TRANSCRIPTION 
OF CYTOKINE GENES 
~[ODULATED TRANSLATION 
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CYTOKINE PROCESSING 
AND SECRETION 
Fig. 6. Simplified cascade of induced cytokine synthesis and secretion. 
thesis is also of crucial importance, but this subject re- 
quires a separate laboration. 
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9. Overall regulation of cytokine synthesis 
Current evidence indicates that tissue injury generates 
multiplicity of alarm molecules which change the environ- 
ment and metabolism of target cells. These changes acti- 
vate stress-sensitive protein kinases and trigger several 
independent and complex kinase cascades. The final phos- 
phorylation concerns transcription factors, the most impor- 
tant belonging to C/EBP, NF-KB and AP-1 families (cf. 
Fig. 5). Enhanced transcription of some cytokine genes 
(TNF, IL-1) occurs often within minutes of the alarming 
signal generation. Variable stability of cytokine mRNA 
and modulation in efficiency of translation are also respon- 
sible for fine regulation of induced expression of cy- 
tokines. Finally, cytokines protein precursors are proteo- 
lytically processed and secreted, and some of them occur 
in circulation in complexed form of different bioavailabil- 
ity. All these factors permit for accurate tuning of cytokine 
synthesis and initiation of the acute phase response (Fig. 
6). It is obvious that almost each of the depicted steps in 
the induced cytokine synthesis may be inhibited by spe- 
cially designed and specific drugs. Since excessive and 
prolonged synthesis of cytokines may result in lethal ef- 
fects or chronic inflammation quenching of cytokine syn- 
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